PharmaPoint: Colorectal Cancer Market Forecast 2023

1. PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023 www.bigmarketresearch.com

2. Report Description Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. Browse complete report & TOC @ http://www.bigmarketresearch.com/pharmapoint-colorectal-cancer-global-drug-forecast-and-analysis-to-2023-market

3. Report Description However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. The CRC market is expected to grow due to the incorporation of five late-stage pipeline agents during the forecast period, including Mologen’s MGN1703, Eli Lilly’s Cyramza, and BoehringerIngelheim’snintedanib. Furthermore, GlobalData expects the label extension of Stivarga as a first-line adjuvant treatment for metastatic CRC patients with resected liver metastases. Ultimately, however, GlobalData expects unmet needs to remain unfulfilled by these pipeline agents, and anticipates that novel, innovative approaches, such as those targeting BRAF mutation-positive disease and immune checkpoint inhibitors, will provide the best opportunity for substantial improvement in the prognosis of advanced CRC patients. Feel free to enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/183885

4. Report Description • Key Questions Answered • What are the corporate strategies being used by drug makers? • How is the disease management evolving.What is the impact for drug manufacturers? • What opportunities remain after the launch of pipeline agents? • How large are the metastatic KRAS wild-type and mutation-positive CRC markets for branded agents, and which are growing the fastest? • What exciting, innovative approaches are being investigated in CRC.Which immunotherapies are of interest to the CRC market? • What do KOLs think about the latest therapies and drug development strategies?

5. Report Description • Key Findings • By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC. • Roche’s anti-angiogenesis drug Avastin has been the best-selling brand in CRC for many years, and, after label extension in the second-line continuation setting, is set to remain the market leader across the forecast period. However, competition in this drug class is expected to become more intense, especially in the second-line metastatic setting, as Sanofi/Regeneron’sZaltrap and Eli Lilly’s pipeline agent Cyramza (ramucirumab) garner uptake across the major markets.

6. Report Description • Key Findings • GlobalData expects the next surge of anti-angiogenesis drugs to be focused on the anti-Ang2 inhibitor class. This class is likely to be led by Roche’s dual anti-VEGF/Ang2 inhibiting antibody vanucizumab (RO5520985; RG7221). Roche is currently investigating vanucizumab head-to-head against Avastin in a randomized Phase II study. If this agent is successful in a large, pivotal study, GlobalData anticipates vanucizumab to become a key part of Roche’s strategy to overcome biosimilar erosion of Avastin towards the end of the forecast period. • Need Discount? Request here @ • http://www.bigmarketresearch.com/purchase-enquiry/183885

7. Table of Contents 4.3 Global Trends 4.3.1 8MM, Incidence Trends 4.3.2 8MM, Five-Year Relative Survival 4.3.3 8MM, Screening Programs for CRC 4.4 Forecast Methodology 4.4.1 Sources Used 4.4.2 Sources Not Used 4.4.3 Forecast Assumptions and Methods 4.5 Epidemiological Forecast of CRC (2013-2023) 4.5.1 Diagnosed Incident Cases of CRC 4.5.2 Age-Specific Diagnosed Incident Cases of CRC 4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 4.5.4 Age-Standardized Incidence 4.5.5 Cancer Stage at Diagnosis 4.5.6 Diagnosed Five-Year Prevalent Cases of CRC 4.5.7 KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC 4.6 Discussion

8. Table of Contents 5 Disease Management 5.1 Diagnosis and Treatment Overview 5.1.1 Screening and Diagnosis 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 5.1.3 Clinical Practice 5.2 US 5.2.1 Screening and Diagnosis 5.2.2 Clinical Practice 5.3 France 5.3.1 Screening and Diagnosis 5.3.2 Clinical Practice 5.4 Germany 5.4.1 Screening and Diagnosis

9. Report Description • Scope • Overview of colorectal cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. • Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023. • Key topics covered include strategic competitor assessment, market characterization, unmet needs, remaining commercial opportunities, and current and future players for the colorectal cancer therapeutics market.

10. Report Description • Scope • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidates in Phase III development are profiled. • Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

11. Report Description • Reasons to buy • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. • Develop business strategies by understanding the trends shaping and driving the global colorectal cancer therapeutics market. • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global colorectal cancer therapeutics market in the future. • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

12. Report Description • Reasons to buy • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

13. FOR MORE DETAILS Visit us at : http://www.bigmarketresearch.com/pharmapoint-colorectal-cancer-global-drug-forecast-and-analysis-to-2023-market Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: help@bigmarketresearch.com